Indication
Solid Tumors With IDH1 Mutation
1 clinical trial
1 product
Clinical trial
A Phase I, Multi-center, Open-label, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of AB-218 for Treating Adult Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2025-08-01
Product
AB-218